This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Adjuvant chemotherapy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is treatment that is given after local treatment of a primary tumour when no metastatic disease is apparent after careful staging, but where there is known to be high incidence of relapse. This relapse is presumed to be due to micrometastases.

For example:

  • adjuvant therapy for breast cancer is any treatment given after primary therapy to increase the chance of long-term disease-free survival
    • adjuvant therapy for breast cancer can include chemotherapy, hormonal therapy, the targeted drug trastuzumab (Herceptin®), radiation therapy, or a combination of treatments.
    • primary therapy is the main treatment used to reduce or eliminate the cancer
    • a well-known example of adjuvant chemotherapy is that has been used for women with stage II (axillary node positive) breast cancer in premenopausal women
      • in this sub-group of patients, at least 65% develop metastatic disease, which is incurable. However if this sub-group is given chemotherapy with CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) then the relapse rate is decreased, and there is a reduction is mortality by approximately 20% (1)

Reference:

  • Brada M, Robinson MH. Medicine International 1991; 92:3834-8.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.